Document And Entity Information
Document And Entity Information | 3 Months Ended |
Sep. 30, 2023 shares | |
Document Information Line Items | |
Entity Registrant Name | America Great Health |
Document Type | 10-Q |
Current Fiscal Year End Date | --06-30 |
Entity Common Stock, Shares Outstanding | 21,107,018,148 |
Amendment Flag | false |
Entity Central Index Key | 0001098009 |
Entity Current Reporting Status | No |
Entity Filer Category | Non-accelerated Filer |
Document Period End Date | Sep. 30, 2023 |
Document Fiscal Year Focus | 2024 |
Document Fiscal Period Focus | Q1 |
Entity Small Business | true |
Entity Emerging Growth Company | false |
Entity Shell Company | false |
Document Quarterly Report | true |
Document Transition Report | false |
Entity File Number | 000-27873 |
Entity Incorporation, State or Country Code | WY |
Entity Tax Identification Number | 98-0178621 |
Entity Address, Address Line One | 1609 W Valley Blvd Unit 338A |
Entity Address, City or Town | Alhambra |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 91803 |
City Area Code | (888) |
Local Phone Number | 988-1333 |
Title of 12(b) Security | N/A |
No Trading Symbol Flag | true |
Security Exchange Name | NONE |
Entity Interactive Data Current | No |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Sep. 30, 2023 | Jun. 30, 2023 |
CURRENT ASSETS | ||
Cash | $ 54,626 | $ 54,150 |
Account receivable, net | 0 | 0 |
Inventory | 108,174 | 108,351 |
Advance to supplier | 16,965 | 16,964 |
TOTAL CURRENT ASSETS | 179,765 | 179,465 |
Right-of-use asset | 23,104 | 41,918 |
Due from the related parties | 8,218 | 8,218 |
Deposit | 11,836 | 11,836 |
Property and equipment, net | 53,995 | 57,692 |
TOTAL ASSETS | 276,918 | 299,129 |
CURRENT LIABILITIES | ||
Accounts payable | 1,448,030 | 1,450,574 |
Income tax payable | 3,410 | 3,970 |
Short term loan | 690,551 | 705,216 |
Other payable | 275,948 | 241,784 |
Due to related party | 484,248 | 425,142 |
Deferred income | 224,570 | 223,331 |
Lease liability - current | 23,104 | 41,918 |
TOTAL CURRENT LIABILITIES | 3,149,861 | 3,091,935 |
Lease liability - non current | 0 | 0 |
Accrued liability | 683,957 | 609,892 |
Long term loan | 1,123,138 | 1,123,138 |
TOTAL LIABILITIES | 4,956,956 | 4,824,965 |
Commitments and Contingencies | 0 | 0 |
SHAREHOLDERS' DEFICIT | ||
Redeemable, convertible preferred stock, 10,000,000 shares authorized; Series A voting preferred stock, zero shares issued and outstanding | 0 | 0 |
Common stock, no par value, unlimited shares authorized; 21,107,018,148 and 21,090,218,148 shares issued and outstanding | 0 | 0 |
Additional paid-in capital | 4,732,477 | 4,732,477 |
Accumulated other comprehensive income | 2,278 | (500) |
Accumulated deficit | (9,339,487) | (9,183,110) |
TOTAL AMERICA GREAT HEALTH SHAREHOLDERS' DEFICIT | (4,604,732) | (4,451,133) |
Non-controlling interest | (75,306) | (74,703) |
TOTAL SHAREHOLDERS' DEFICIT | (4,680,038) | (4,525,836) |
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT | $ 276,918 | $ 299,129 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - shares | Sep. 30, 2023 | Jun. 30, 2023 |
Statement of Financial Position [Abstract] | ||
Series A voting preferred stock, shares issued | 0 | 0 |
Series A voting preferred stock, shares outstanding | 0 | 0 |
Redeemable, convertible preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Common stock, shares issued | 21,107,018,148 | 21,090,218,148 |
Common stock, shares outstanding | 21,107,018,148 | 21,090,218,148 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Income - USD ($) | 3 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Income Statement [Abstract] | ||
Sales | $ 13,808 | $ 51,938 |
Cost of goods sold | 177 | 27,500 |
Gross profit | 13,631 | 24,438 |
Selling, general and administrative expenses | ||
Selling expense | 64 | 4,736 |
General and administrative expense | 88,505 | 147,923 |
88,569 | 152,659 | |
Loss from operations | (74,938) | (128,221) |
Other income (expenses) | ||
Interest expense | (82,049) | (64,539) |
Other income | 7 | 6 |
(82,042) | (64,533) | |
Loss before income taxes | (156,980) | (192,754) |
Income tax provision | 0 | 0 |
NET LOSS | (156,980) | (192,754) |
Less: net loss attributable to non-controlling interest | (603) | (10,418) |
NET LOSS ATTRIBUTABLE TO AMERICA GREAT HEALTH | (156,377) | (182,336) |
Foreign currency transaction | 2,278 | 76 |
COMPREHENSIVE LOSS ATTRIBUTABLE TO AMERICA GREAT HEALTH | $ (154,099) | $ (182,260) |
BASIC AND DILUTED LOSS PER SHARE (in Dollars per share) | $ 0 | $ 0 |
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED (in Shares) | 21,093,818,148 | 21,090,218,148 |
Consolidated Statement of Chang
Consolidated Statement of Changes in Shareholders' Deficit - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Noncontrolling Interest [Member] | AOCI Attributable to Parent [Member] | Total |
Balance at Jun. 30, 2022 | $ 4,619,991 | $ (8,421,849) | $ 58,783 | $ 160 | $ (3,860,481) | |
Balance (in Shares) at Jun. 30, 2022 | 21,090,218,148 | |||||
Imputed Interest | 5,206 | 5,206 | ||||
OID | 15,200 | 15,200 | ||||
Gain/loss on exchange rate | 76 | 76 | ||||
Net loss | (182,336) | (10,418) | (192,754) | |||
Balance at Sep. 30, 2022 | 4,640,397 | (8,604,185) | (69,201) | 236 | (4,032,753) | |
Balance (in Shares) at Sep. 30, 2022 | 21,090,218,148 | |||||
Balance at Jun. 30, 2023 | 4,732,477 | (9,183,110) | (74,703) | (500) | $ (4,525,836) | |
Balance (in Shares) at Jun. 30, 2023 | 21,107,018,148 | 21,090,218,148 | ||||
Imputed Interest | $ 0 | |||||
Gain/loss on exchange rate | 2,778 | 2,778 | ||||
Net loss | (156,377) | (603) | (156,980) | |||
Balance at Sep. 30, 2023 | $ 4,732,477 | $ (9,339,487) | $ (75,306) | $ 2,278 | $ (4,680,038) | |
Balance (in Shares) at Sep. 30, 2023 | 21,107,018,148 | 21,107,018,148 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 3 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Cash Flows from Operating Activities | ||
Net loss | $ (156,980) | $ (192,754) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 3,697 | 1,476 |
Original issue discount on debt | 0 | 15,200 |
Imputed interest | 0 | 5,206 |
Changes in operating Assets and Liabilities: | ||
Accounts receivable | 0 | 273 |
Prepaid investment | 0 | 0 |
Other receivable | 0 | 0 |
Other long term asset | (20,210) | |
Inventory | 177 | (5,447) |
Accounts payable | (2,544) | (3,280) |
Customer advances | 1,240 | 13,000 |
Other liabilities | 27,137 | |
Other payable | 33,602 | 16,143 |
Income tax payable | 12 | |
Net cash used in operating activities | (120,808) | (143,244) |
Cash Flows from Investing Activities | ||
Purchase of property and equipment | 0 | 0 |
Net cash provided by investing activities | 0 | 0 |
Cash Flows from Financing Activities | ||
Repayment of short term loan | (14,664) | (30,595) |
Proceeds of long term loan | 74,064 | 152,924 |
Advances from related party | 77,470 | 104,706 |
Repayment to related party | (18,364) | (71,938) |
Net cash provided by financing activities | 118,506 | 155,097 |
Effect of exchange rate change on cash | 2,778 | 76 |
Net increase in cash | 476 | 11,929 |
Cash beginning of period | 54,150 | 62,643 |
Cash end of period | 54,626 | 74,572 |
Interest paid | 0 | 0 |
Taxes paid | 800 | 800 |
Non-cash transactions | ||
Shares issued for equity investment | $ 0 | $ 0 |
NATURE OF BUSINESS
NATURE OF BUSINESS | 3 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | NOTE 1 NATURE OF BUSINESS History and Organization America Great Health, formerly Crown Marketing, is a Wyoming corporation (the "Company"). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations. On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health. On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California. On June 24, 2019, the Company registered a wholly owned subsidiary in China, US-China Mega Beauty Health Industry Development Co., LTD. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China. On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day-to-day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. This transaction was completed in May 2021. On December 7, 2020, the Company’s wholly-owned Californian subsidiary, America Great Health, entered into a Cooperation Agreement with Brilliant Healthcare Limited (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, raw material procurement, mergers and acquisitions, and consulting services. After the formation of the JV company is completed, the Company shall invest US$4.2 million in the JV Company within the next 24 months for a 60% equity ownership in the JV Company. Brilliant shall transfer its patented technology to the JV Company as its capital contribution, to account for a 40% equity interest in the JV Company. As a condition for AAGH to obtain 60% equity in the JV company and a as the founder of Brilliant, Dr. Aihua Guo agrees to transfer its patent to the JV company as its share of contribution, and AAGH also agrees to pay Dr. Aihua Guo additional compensation, which includes: (i) AAGH transfers 300 million original shares of AAGH to Dr. Aihua Guo at no cost, valuing at $15 million; (ii) AAGH pays Dr. Aihua Guo a one-time cash compensation of $3 million with the following payment schedule: AAGH agrees to pay $500,000 to Dr. Aihua Guo six months from the date of signing of this Agreement, $1.5 million to Dr. Aihua Guo 12 months from the date of signing of this Agreement, and $1 million to Dr. Aihua Guo 24 months from the date of signing of this Agreement. In June 2021, the JV Company was established in Hainan, China as “Sijinsai (Hainan) Biological Tech Ltd.” On July 9, 2021, the Company paid its first investment of $50,000. On May 18, 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology. Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. Currently, several patents are in the application process, and several products are in the process of getting ready for production. On September 3, 2021, the Company entered into an Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to purchase 53 units in 19 real estate properties appraised at $7,626,286.37 for a purchase price of $7,000,000. The purchase price shall be paid as follows: (i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence. On September 9, 2021, the Company entered into a Supplemental Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to amend and clarify that (i) it was purchasing 19 real estate properties which includes 53 units appraised at $7,626,286.37 for a purchase price of $7,000,000 and (ii) that it will waive and not conduct due diligence in order for the transaction to proceed. The acquisition has not been consummated. On November 4, 2021, the Company set up a 100% owned subsidiary Nutrature Health LLC. On November 11, 2021, America Great Health (the “Company”) entered into an Advisory Committee Member Consulting Agreement with Dr. Kevin Buckman MD (“Consultant”). Pursuant to the Agreement, Consultant is to provide advisory services, as a member to the Advisory Committee to the Board of Directors of the Company, including without limitation, assisting GOF Biotechnologies Inc. in its new drug approval process for oral insulin and Amylase X. Consultant shall be compensated with a warrant to purchase 500,000 shares of the Company at $0.01 per share within 24 months and a warrant at each of the following stages: IND application, Phase I clinical trials, Phase II clinical trials, Phase III clinical trials and the sale of GOF Biotechnologies Inc. the license of oral insulin and Amylase X at Phase I or Phase II clinical trials stages. This Agreement shall be for an initial one-year term and shall renew automatically for successive one-year terms up to a maximum of three (3) years unless terminated by either party pursuant to the Agreement. The 500,000 shares were issued free in April 20, 2022. On November 15, 2021, the Company set up a 100% owned subsidiary GOF Biotechnologies Inc. GOF is 75% majority owned (60,000,000 shares of common stock) by the Company and the remaining 25% of its issued and outstanding shares (20,000,000 shares of common stock) are held by Men Hwei, Tsai. On December 31, 2021, the Company entered into a Supplementary Agreement with Zhigong Lin to amend his prior employment agreement with the Company dated August 31, 2021. The Supplement Agreements provides, inter alia, that Zhigong Lin will be appointed Chief Executive Officer of GOF. The employment agreement and supplement agreement were both terminated by the end of July without the issuance of any GOF shares. On February 4, 2021, the Company set up a 100% owned subsidiary, International Institute of Great Healthcare, Inc. (“IIGH”) under the laws of the State of California. IIGH will bring together doctors and professional-level experts from different countries and regions in the world to the research fields involving bio medicine, clinic medicine, health management, information technology, data analysis, software development, artificial intelligence, industrial planning, financial investment, etc. On November 25,2022, the Company signed a supplementary agreement with Men Hwei, Tsai who is an unrelated party. The Company A agrees that if the patent is sold or transferred, Men Hwei, Tsai or Men Hwei, Tsai's successor may receive a 25% gain on the transfer or sale of the interest. The Company agrees to give Men Hwei, Tsai an additional 20 million AAGH shares. The Company allows Men Hwei, Tsai to use three years (from November 26, 2022 to November 25, 2025) find investors each with more than US$10 million investment. In case that no investor is found within three years, Men Hwei, Tsai agrees to return the patent to the Company, and both parties will continue to cooperate in accordance with the original contract on May 18, 2021. If Men Hwei, Tsai finds an investor with an investment of at least US$10 million within three years, and the process for Men Hwei, Tsai and its investors to apply for a new drug may last for several years, then Men Hwei, Tsai agrees that the Company will use the patented technology to develop dietary supplement that are helpful to Alzheimer’s disease. The Company will be responsible for marketing the dietary supplement. Men Hwei, Tsai is entitled to commission equaling to 8% of sales price. On November 26, 2022, the Company signed a supplementary agreement with Men Hwei, Tsai who is an unrelated party and transferred pending anti-dementia patent to Men Hwei, Tsai for $34,978.48. Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has incurred recurring net losses. For the three months ended September 30, 2023, the Company recorded a net loss of $156,980, used cash to fund operating activities of $120,808, and at September 30, 2023, had a shareholders’ deficit of $4,680,038. These factors create substantial doubt about the Company’s ability to continue as a going concern within the next twelve months from the date these financial statements are available to be issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. During the year ended June 30, 2017, the Company’s former majority shareholder sold his shares to an investor group. The new owners’ plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations. Our cash needs for the three months ended September 30, 2023 were primarily met by loans and advances from the current majority shareholder. As of September 30, 2023, we had a cash balance of $54,626. We intend to finance operating costs over the next twelve months with existing cash on hand and advance from current majority shareholder. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 3 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies [Text Block] | NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). The accompanying unaudited condensed consolidated financial statements of America Great Health, formerly Crown Marketing and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2024. Basis of Consolidation The Condensed Consolidated Financial Statements includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California (100%), GOF Biotechnologies in California (75%), International Institute of Great Health in California (100%), Nutrature Health LLC in California (100%), Sijinsai in China (60%), and US-China Mega Beauty Health Industry Development Co., LTD, (100%). Intercompany transactions and accounts were eliminated in consolidation. The following table depicts the identity of the Company’s subsidiaries: Attributable Place of Equity Name of Subsidiary Incorporation Interest % America Great Health in California USA 100 GOF Biotechnologies in California USA 75 International Institute of Great Health in California USA 100 Nutrature Health LLC in California USA 100 Sijinsai in China CHINA 60 US-China Mega Beauty Health Industry Development Co., LTD CHINA 100 Estimates The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services, debt and equity investment. Actual results could differ from those estimates. Foreign Currency Translation Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations. In accordance with ASC 830, “Translation of Financial Statements” the subsidiary’s assets and liabilities booked and recorded at the non-US local functional currency are generally translated into USD for consolidation purposes, using the exchange rate on the balance sheet date, and revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of foreign subsidiary’s financial statements are recorded as a separate component of accumulated other comprehensive income within the statement of stockholders’ equity. The Company’s reporting currency is the United States Dollar (“USD”). The Company’s wholly owned subsidiary of US-China Mega Beauty Health Industry Development Co., LTD. maintains its books and records in its local currency. The Chinese Yuan (“RMB”), which is the functional currency as being the primary currency of the economic environment in which the subsidiary operates. Below is a table with foreign exchange rates used for translation: September 30, 2023 Average Quarterly (average rate) Chinese Renminbi (RMB) RMB 7.2414 United States dollar ($) $ 1.00 September 30, 2023 Quarter Ended (Closing rate) Chinese Renminbi (RMB) RMB 7.2948 United States dollar ($) $ 1.00 Cash The Company considers all highly liquid debt instruments purchased with maturity periods of six months or less to be cash equivalents. The carrying amounts reported in the accompanying balance sheet for cash and cash equivalents approximate their fair value. The Company’s bank account in the United States is protected by FDIC insurance. The Company’s bank account in the United States is protected by FDIC insurance. As of September 30, 2023 and June 30, 2023, the Company’s bank account in the United States had $3,884 and $4,087, respectively, within FDIC insurance of $250,000. Revenues Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, ● executed contract(s) with customers that the Company believes is legally enforceable; ● identification of performance obligation in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation of the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. The Company sells health related products through wholesale and retailers. Substantially all of the Company’s revenue is derived from product sales. The Company considers purchase orders to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year, and virtually all of the Company’s contracts are short-term. The Company recognizes revenue for the transfer of promised goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Company typically satisfies its performance obligations in contracts with customers upon shipment of the goods. The Company does not have any contract assets since the Company has an unconditional right to consideration when the Company has satisfied its performance obligation and payment from customers is not contingent on a future event. Generally, payment is due from customers within 40 to 60 days of the invoice date, and the contracts do not have significant financing components nor variable consideration. Returns and allowances are not a significant aspect of the revenue recognition process as historically they have been immaterial. All of the Company’s contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as a price per unit. All estimates are based on the Company’s historical experience; complete satisfaction of the performance obligation, and the Company’s best judgment at the time the estimate is made. Historically, sales returns have not significantly impacted the Company’s revenue. Product Revenue A majority of the Company’s sales are for products sold at a point in time and shipped to customers, for which control is transferred to the customer as goods are delivered to the third-party carrier for shipment. The Company receives payment for the sale of products at the time customers place orders and payment is required prior to shipment. The Company does not recognize assets associated with costs to obtain or fulfill a contract with a customer. Shipping and handling activities are performed upon delivery to the third-party carrier for shipment. The Company accounts for these activities as fulfillment costs. Therefore, the Company recognizes the costs of these activities when revenue for the goods is recognized. Shipping and handling costs are included in cost of sales for all periods presented. Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances. For the three months ended September 30, 2023 and 2022, the Company has not made provision for inventory in regards to slow moving or obsolete items. As of September 30, 2023 and June 30, 2023, inventories amounted to $108,174 and $108,351, respectively. Equity Method Investments We apply the equity method of accounting to investments when we have significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “equity investment” in our Consolidated Statements of Operations. The carrying value of our equity method investments is reported in equity investment in the Consolidated Balance Sheets. The Company’s equity method investments are reported at cost and adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company’s share of the investee’s income or loss is recorded on a one quarter lag for all equity method investments. The Company classifies distributions received from equity method investments using the cumulative earnings approach on the Consolidated Statements of Cash Flows. The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. The Company recorded no other-than-temporary impairment charges related to its equity method investments during the three months ended September 30, 2023 and 2022. Fair Value Measurements Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if available without undue cost and effort. The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature. Loss per Share Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the three months ended September 30, 2023 and 2022, as there are no potential shares outstanding that would have a diluted effect. Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company did not record a valuation allowance against its deferred tax assets as of September 30, 2023, and June 30, 2023. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. Recent Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update 2017-11, “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II)”, which is the replacement of the Indefinite Deferral for Mandatory Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatory Redeemable Non-controlling Interests with a Scope Exception. The amendments in Part I of this Update that relate to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include down round features affect entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in Part II of this Update do not have an accounting effect. The amendments in Part I of the update are effective for fiscal year, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is assessing the impact to its accounting practices and financial reporting procedures as a result of the issuance of this standard. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements. |
DEPOSITS
DEPOSITS | 3 Months Ended |
Sep. 30, 2023 | |
Receivables [Abstract] | |
Loans, Notes, Trade and Other Receivables Disclosure [Text Block] | NOTE 3 DEPOSITS As of September 30, 2023 and June 30, 2023, deposits amounted to $11,836. |
INVENTORY
INVENTORY | 3 Months Ended |
Sep. 30, 2023 | |
Inventory Disclosure [Abstract] | |
Inventory Disclosure [Text Block] | NOTE 4 INVENTORY As of September 30, 2023 and June 30, 2023, inventory consisted of the following: September 30, June 30, 2023 2023 Raw materials $ 65,900 $ 65,900 Finished goods 42,274 42,451 Total Inventory $ 108,174 $ 108,351 |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 3 Months Ended |
Sep. 30, 2023 | |
Related Party Transactions [Abstract] | |
Related Party Transactions Disclosure [Text Block] | NOTE 5 RELATED PARTY TRANSACTIONS During the three months ended September 30, 2023, the Company's current majority shareholder advanced $77,470 to the Company as working capital and the Company repaid $18,364 to the shareholder. As of September 30, 2023 and June 30, 2023, the Company owed its current majority shareholder $484,248 and $425,142, respectively. The advances are non-interest bearing and are due on demand. Imputed interest amounted to $0 and $5,206 for the three months ended September 30, 2023 and 2022 and was recorded as paid in capital, respectively. |
SHORT TERM LOAN
SHORT TERM LOAN | 3 Months Ended |
Sep. 30, 2023 | |
Debt Disclosure [Abstract] | |
Short-Term Debt [Text Block] | NOTE 6 SHORT TERM LOAN As of September 30, 2023 and June 30, 2023, short term loan amounted to $690,551 and $705,216 from unrelated third parties, respectively. |
LONG TERM LOAN
LONG TERM LOAN | 3 Months Ended |
Sep. 30, 2023 | |
Debt Disclosure [Abstract] | |
Long-Term Debt [Text Block] | NOTE 7 LONG TERM LOAN As of September 30, 2023 and June 30, 2023, long term loan both amounted to $1,123,138. The loan has an annual interest rate of 20%, except that the received long term loan on September 9, 2022 has an annual interest rate of 16%. The principal and interest are due in five years. Interest expense incurred for the three months ended September 30, 2023 and 2022 amounted to $56,618 and $52,924, respectively. As of September 30, 2023, long term loan consisted of the following: Principal Interest Balance Received long term loan on April 27, 2021 $ 200,000 $ 97,096 $ 297,096 Received long term loan on June 3, 2021 290,000 134,910 424,910 Received long term loan on June 4, 2021 50,000 23,260 73,260 Received long term loan on June 23, 2021 30,000 13,627 43,627 Received long term loan on July 12, 2021 10,000 4,438 14,438 Received long term loan on September 1, 2021 60,000 24,953 84,953 Received long term loan on September 22, 2021 50,000 20,219 70,219 Received long term loan on September 27, 2021 50,000 20,082 70,082 Received long term loan on September 30, 2021 10,000 4,000 14,000 Received long term loan on October 29, 2021 12,138 4,662 16,800 Received long term loan on November 9, 2021 50,000 18,904 68,904 Received long term loan on November 16, 2021 140,000 52,395 192,395 Received long term loan on November 18, 2021 50,000 18,658 68,658 Received long term loan on November 29, 2021 20,000 7,342 27,342 Received long term loan on November 30, 2021 10,000 3,666 13,666 Received long term loan on October 13, 2022 21,000 4,050 25,050 Received long term loan on March 10, 2023 10,000 1,118 11,118 Received long term loan on March 14, 2023 10,000 1,096 11,096 Received long term loan on March 16, 2023 10,000 1,085 11,085 Received long term loan on April 17, 2023 30,000 2,729 32,729 Received long term loan on May 9, 2023 10,000 789 10,789 Total $ 1,123,138 $ 459,079 $ 1,582,217 On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on April 27, 2021. On May 31, 2021, the Company agreed 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed $20,000 on June 3, 2021 and $30,000 on June 23, 2021 and issued 200,000 shares on June 18, 2021 and 240,000 shares on October 28, 2021 with 60,000 shares unissued. On June 18, 2021, the Company issued an aggregate of 2,850,000 shares to 5 unrelated parties as collateral for loans of $270,000. One party with a loan of $100,000 was also awarded 100,000 bonus shares beside the 1,000,000 shares. The loans have an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 3, 2021. On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on June 4, 2021. On October 28, 2021, the Company issued 80,000 shares to an unrelated party as collateral for loans of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on July 12, 2021. On October 28, 2021, the Company issued 1,540,000 shares to an unrelated party as collateral for loans of $60,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 1, 2021. On October 28, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 22, 2021. On November 22, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed in September 27, 2021. On November 22, 2021, the Company issued 100,000 shares to an unrelated party as collateral for loans of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in one year. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on September 30, 2021. On November 22, 2021, the Company issued 161,840 shares to an unrelated party as collateral for loans of $12,138. The loan has an annual interest rate of 20%. The principal and interest are due in one year. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on October 29, 2021. On November 22, 2021, the Company issued 400,000 shares to an unrelated party as collateral for loans of $40,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 16, 2021. On November 22, 2021, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 9, 2021. On November 29, 2021, the Company issued 1,000,000 shares to an unrelated party as collateral for a loan of $100,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 16, 2021. On February 2, 2022, the Company issued 500,000 shares to an unrelated party as collateral for loans of $50,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 19, 2021. On February 2, 2022, the Company issued 200,000 shares to an unrelated party as collateral for loan of $20,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 29, 2021. On February 2, 2022, the Company issued 100,000 shares to an unrelated party as collateral for loan of $10,000. The loan has an annual interest rate of 20%. The principal and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received the proceed on November 30, 2021. On September 9, 2022, the Company signed a loan agreement of $100,000 with a five-year term from an unrelated party for a freeze-dryer. The loan has an annual interest rate of 16% with the payments of $3,000 at the end of every month starting the fourth month after the Company received the proceed and the final payment of $12,000 on September 9, 2027. The Company received the proceed on September 9, 2022. This loan was returned and $4,953 of accrued interest was paid on January 13, 2023. On October 13, 2022, the Company signed a loan agreement of $21,000 with Lian Chen who is an unrelated party. The loan has an annual interest rate of 20%. Total principal and interest of $42,000 are due in five years. The unrelated party would receive 2,625,000 shares from a shareholder designated by the Company. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. The Company received $21,000 loan on October 13, 2022. On October 21, 2022, the Company's current majority shareholder Mike Q. Wang transferred 2,625,000 shares to Lian Chen. If after five years, Lian Chen chooses to use stocks to offset the loan, then the Company will issue 2,625,000 shares of common stock to Mike Wang. On January 13, 2023, the Company signed a loan agreement of $150,000 with a one-year term from an unrelated party. The loan has an annual interest rate of 20%. Total principal and interest of $30,000 are due in one year. On January 24, 2023, the Company signed a loan agreement of $300,000 with a one-year term from an unrelated party. The loan has an annual interest rate of 20%. A total principal and interest of $60,000 are due in one year. On March 10, 2023, the Company signed a loan agreement of $10,000 with a three-year term from an unrelated party. The loan has an annual interest rate of 20%. Total principal and interest of $6,000 are due in three years. The unrelated party would receive 1,000,000 shares from a shareholder designated by the Company. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can normally be traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of the loan will be forgiven. As of the issue of this Form 10Q, the 1,000,000 shares have not been issued. On March 14, 2023, the Company signed a loan agreement of $10,000 with a three-year term from an unrelated party. The loan has an annual interest rate of 20%. Total principal and interest of $6,000 are due in three years. The unrelated party would receive 1,000,000 shares from a shareholder designated by the Company. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can normally be traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of the loan will be forgiven. The 1,000,000 shares were issued on April 18, 2023. On March 16, 2023, the Company signed a loan agreement of $10,000 with a three-year term from an unrelated party. The loan has an annual interest rate of 20%. Total principal and interest of $6,000 are due in three years. The unrelated party would receive 1,000,000 shares from a shareholder designated by the Company. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can normally be traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of the loan will be forgiven. The 1,000,000 shares were issued on April 18, 2023. On April 17, 2023, the Company signed a loan agreement of $30,000 with a three-year term from an unrelated party. The loan has an annual interest rate of 20%. A total principal and interest of $18,000 are due in three years. The unrelated party would receive 6,000,000 shares from a shareholder designated by the Company. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can normally be traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of the loan will be forgiven. As of the issue of this Form 10Q, 6,000,000 shares have not been issued. On May 9, 2023, the Company signed a loan agreement of $10,000 with a three-year term from an unrelated party. The loan has an annual interest rate of 20%. A total principal and interest of $6,000 are due in three years. The unrelated party would receive 1,000,000 shares from a shareholder designated by the Company. The shares issued are restricted and will be returned to the Company after the principal and interest are paid in full. During the investment period, if the stock can normally be traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of the loan will be forgiven. As of the issue of this Form 10Q, the 1,000,000 shares have not been issued. |
CONVERTIBLE, REDEEMABLE PREFERR
CONVERTIBLE, REDEEMABLE PREFERRED STOCK | 3 Months Ended |
Sep. 30, 2023 | |
Disclosure Text Block Supplement [Abstract] | |
Preferred Stock [Text Block] | NOTE 8 CONVERTIBLE, REDEEMABLE PREFERRED STOCK During the year ended June 30, 2016, the Company’s Board of Directors authorized the creation of a series of preferred stock consisting of 1,000,000 shares designated as Series A Preferred Stock (the “Series A”). The Series A is entitled to a dividend of 4%, when and as declared, and is entitled to a liquidation preference of $1 per share plus unpaid dividends. The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”). In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days. The Series A is also subject to adjustments to the Conversion Rate. If the common stock issuable on conversion of the Series A is changed into the same or a different number of shares of any other class or classes of stock, whether by capital reorganization, reclassification, or otherwise (other than a subdivision or combination of shares provided for above), the holders of the Series A shall, upon its conversion, be entitled to receive, in lieu of the common stock which the holders would have become entitled to receive but for such change, a number of shares of such other class or classes of stock that would have been subject to receipt by the holders if they had exercised their rights of conversion of the Series A immediately before that change. In August 2016, the Company filed an amendment to its Articles of Incorporation to increase the number of authorized shares of Series A Preferred Stock from 1,000,000 to 10,000,000. There were no preferred shares outstanding as of September 30, 2023 and June 30, 2023. |
SHAREHOLDERS' DEFICIT
SHAREHOLDERS' DEFICIT | 3 Months Ended |
Sep. 30, 2023 | |
Stockholders' Equity Note [Abstract] | |
Equity [Text Block] | NOTE 9 SHAREHOLDERS DEFICIT At September 30, 2023 and June 30, 2023, the Company had 21,107,018,148 and 21,090,218,148 shares issued and outstanding, respectively. 1) Shares issued for equity investment On April 6, 2021, the Company issued 70,000,000 shares to a director of Imediplus as collateral in exchange for getting trust of 2,500,000 shares that is 5% of Imediplus. The transaction has not been completed by the reporting date. Equity Investment in Purecell Group: On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Because the company does not have significant control over Purecell, so this is an equity investment. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell") in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000 shares of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in place, the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000 shares for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP, at fair market value of $0.00001 per share. On March 31, 2022, the Company issued 1,300,000 shares of common stock to an US individual at $0.075 per share. 2) Shares issued for stock compensation None 3) Shares issued for short term loan as original issue discount None 4) Shares issued for loan as collateral None 5) Shares issued in exchange for payable balance None |
EQUITY INVESTMENT
EQUITY INVESTMENT | 3 Months Ended |
Sep. 30, 2023 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | NOTE 10 EQUITY INVESTMENT On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Because the company does not have significant control over Purecell, so this is an equity investment. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell" ) in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at fair market value of $0.00001 per share. On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. In order to complete the change of 35,000,000 shares of the Company held by Purecell to AP within the agreed time limit, and to meet the conditions that AP investment funds are in place, the Company and Purecell agreed through consultation that in order to gain time, the Company will issue an additional 35,000,000 shares for AP. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP, at fair market value of $0.00001 per share. The following table summarizes the income statement of Purecell. From 07/01/2023 to 09/30/2023 (Unaudited) Sales $ - Gross profit 22,869 Net loss (67,871 ) 51% share (36,614 ) The following table provides the summary of equity investment in Purecell. As of September 30, 2023 (Unaudited) Total assets $ 3,223,885 Net assets 2,248,575 51% ownership 1,146,773 Beginning balance of investment 5,450 Loss on equity investment (5,450 ) Ending balance of investment - |
INCOME TAXES
INCOME TAXES | 3 Months Ended |
Sep. 30, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Tax Disclosure [Text Block] | NOTE 11 INCOME TAXES As of September 30, 2023, the Company had federal and California income tax net operating loss carryforwards of approximately $6.5 million. These net operating losses will begin to expire 20 years from the date the tax returns are filed. Uncertain Tax Positions Interest associated with unrecognized tax benefits are classified as income tax, and penalties are classified in selling, general and administrative expenses in the statements of operations. For the three months ended September 30, 2023 and 2022, the Company had no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions. |
LEASE
LEASE | 3 Months Ended |
Sep. 30, 2023 | |
Disclosure Text Block [Abstract] | |
Lessee, Operating Leases [Text Block] | NOTE 12 LEASE The Company has entered into a operating leases agreement with GKT, Alhambra, LP. The lease term of the office space is from December 1, 2020 to November 30, 2023. The current monthly rent including monthly management fee is $4,655.64. The operating lease is listed as separate line item on the Company’s condensed consolidated financial statements and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make lease payments are also listed as a separate line item on the Company’s condensed consolidated financial statements. The Company has entered into an operating lease agreement with SoCal Industrial LLC, Irwindale. The lease term of the office space is from June 1, 2023 to May 31, 2024 after the prior lease expired on May 31, 2023. The current monthly rent including monthly management fee is $1,764.00. The operating lease is listed as a separate line item on the Company’s condensed consolidated financial statements and represents the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make lease payments is also listed as a separate line item on the Company’s condensed consolidated financial statements. Operating lease right-of-use assets and liabilities commencing after December 1, 2020 are recognized at commencement date based on the present value of lease payments over the lease term. For the three months ended September 30, 2023, the Company recognized approximately $20,277 in total lease costs. Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. Information related to the Company’s operating ROU assets and related lease liabilities are as follows: Three months ended September 30, 2023 Cash paid for operating lease liabilities $ 18,896 Weighted-average remaining lease term 1.04 Weighted-average discount rate 5 % Minimum future lease payments $ 23,423 The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending September 30: 2023 $ 14,603 2024 8,820 2025 - 2026 - Total minimum payments 23,423 Less: imputed interest (319 ) Total lease liability 23,104 Less: short-term lease liability (23,104 ) Long-term lease liability $ - |
CONCENTRATION
CONCENTRATION | 3 Months Ended |
Sep. 30, 2023 | |
Risks and Uncertainties [Abstract] | |
Concentration Risk Disclosure [Text Block] | NOTE 13 CONCENTRATION Major vendors For the year ended September 30, 2023, no vendors accounted for 10% or more of the Company’s purchases and its outstanding accounts payable balances as at year-end dates. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 3 Months Ended |
Sep. 30, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | NOTE 14 SUBSEQUENT EVENTS On July 23, 2023, the Company, SHOWA International Pty Ltd. (“SHOWA”), and Jeffery Tu & Eric Hsu, entered into a Cooperation Agreement (the “Agreement”), in which three parties shall establish a strategic partnership in Japan to produce and promoting Bio-active Protein Peptide in Japan. SHOWA, as a Japanese based company, shall use its best effort in promoting the Company’s Bio-active Protein Peptide and related products in Japan, and shall be in charge of the overall marketing strategy, day-to-day business operations, products design, public relations, etc. As the Company’s exclusive strategic partner in Japan, SHOWA shall be responsible for marketing and promoting all of the Company’s Bio-active Protein Peptide and related products within the territory of Japan and other mutually agreed regions. In addition, SHOWA shall achieve the following milestones in sales during the next four-year period of time: 150,000 bottles during year one, 300,000 bottles during year two, 600,000 during year three, 1,000,000 bottles during year four. On October 04, 2023, the Company entered into a New Drugs Application and Joint Venture Agreement (the “Agreement”), with CIMC Automatic Control System Technology (Liaoning) Co., Ltd. (“CIMC”), in which both parties agree to establish a joint venture in Beijing, China aiming to develop and promote the Bio-active Protein Peptide supplements and Peptide medicinal in China (“New Venture”). Upon execution of the Agreement, the Company shall contribute its technologies and marketing assistance, and owns 30% of total outstanding shares of the New Venture; CIMC shall contribute all required working capital and other resources and owns 70% of total outstanding shares of the New Venture. The total registered capital of the New Venture shall be $10 million RMB. CIMC shall also be responsible for all required capital in the new drugs application and approval process which is approximately 200 million RMB. Both parties further agree that the New Venture shall distribute 10% of its net profit to the Company annually for R&D and product productions. |
Accounting Policies, by Policy
Accounting Policies, by Policy (Policies) | 3 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). The accompanying unaudited condensed consolidated financial statements of America Great Health, formerly Crown Marketing and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending June 30, 2024. |
Consolidation, Policy [Policy Text Block] | Basis of Consolidation The Condensed Consolidated Financial Statements includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California (100%), GOF Biotechnologies in California (75%), International Institute of Great Health in California (100%), Nutrature Health LLC in California (100%), Sijinsai in China (60%), and US-China Mega Beauty Health Industry Development Co., LTD, (100%). Intercompany transactions and accounts were eliminated in consolidation. The following table depicts the identity of the Company’s subsidiaries: Attributable Place of Equity Name of Subsidiary Incorporation Interest % America Great Health in California USA 100 GOF Biotechnologies in California USA 75 International Institute of Great Health in California USA 100 Nutrature Health LLC in California USA 100 Sijinsai in China CHINA 60 US-China Mega Beauty Health Industry Development Co., LTD CHINA 100 |
Use of Estimates, Policy [Policy Text Block] | Estimates The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services, debt and equity investment. Actual results could differ from those estimates. |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign Currency Translation Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations. In accordance with ASC 830, “Translation of Financial Statements” the subsidiary’s assets and liabilities booked and recorded at the non-US local functional currency are generally translated into USD for consolidation purposes, using the exchange rate on the balance sheet date, and revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of foreign subsidiary’s financial statements are recorded as a separate component of accumulated other comprehensive income within the statement of stockholders’ equity. The Company’s reporting currency is the United States Dollar (“USD”). The Company’s wholly owned subsidiary of US-China Mega Beauty Health Industry Development Co., LTD. maintains its books and records in its local currency. The Chinese Yuan (“RMB”), which is the functional currency as being the primary currency of the economic environment in which the subsidiary operates. Below is a table with foreign exchange rates used for translation: September 30, 2023 Average Quarterly (average rate) Chinese Renminbi (RMB) RMB 7.2414 United States dollar ($) $ 1.00 September 30, 2023 Quarter Ended (Closing rate) Chinese Renminbi (RMB) RMB 7.2948 United States dollar ($) $ 1.00 |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash The Company considers all highly liquid debt instruments purchased with maturity periods of six months or less to be cash equivalents. The carrying amounts reported in the accompanying balance sheet for cash and cash equivalents approximate their fair value. The Company’s bank account in the United States is protected by FDIC insurance. The Company’s bank account in the United States is protected by FDIC insurance. As of September 30, 2023 and June 30, 2023, the Company’s bank account in the United States had $3,884 and $4,087, respectively, within FDIC insurance of $250,000. |
Revenue [Policy Text Block] | Revenues Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, ● executed contract(s) with customers that the Company believes is legally enforceable; ● identification of performance obligation in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation of the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. The Company sells health related products through wholesale and retailers. Substantially all of the Company’s revenue is derived from product sales. The Company considers purchase orders to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year, and virtually all of the Company’s contracts are short-term. The Company recognizes revenue for the transfer of promised goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods. The Company typically satisfies its performance obligations in contracts with customers upon shipment of the goods. The Company does not have any contract assets since the Company has an unconditional right to consideration when the Company has satisfied its performance obligation and payment from customers is not contingent on a future event. Generally, payment is due from customers within 40 to 60 days of the invoice date, and the contracts do not have significant financing components nor variable consideration. Returns and allowances are not a significant aspect of the revenue recognition process as historically they have been immaterial. All of the Company’s contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as a price per unit. All estimates are based on the Company’s historical experience; complete satisfaction of the performance obligation, and the Company’s best judgment at the time the estimate is made. Historically, sales returns have not significantly impacted the Company’s revenue. Product Revenue A majority of the Company’s sales are for products sold at a point in time and shipped to customers, for which control is transferred to the customer as goods are delivered to the third-party carrier for shipment. The Company receives payment for the sale of products at the time customers place orders and payment is required prior to shipment. The Company does not recognize assets associated with costs to obtain or fulfill a contract with a customer. Shipping and handling activities are performed upon delivery to the third-party carrier for shipment. The Company accounts for these activities as fulfillment costs. Therefore, the Company recognizes the costs of these activities when revenue for the goods is recognized. Shipping and handling costs are included in cost of sales for all periods presented. |
Inventory, Policy [Policy Text Block] | Inventories Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances. For the three months ended September 30, 2023 and 2022, the Company has not made provision for inventory in regards to slow moving or obsolete items. As of September 30, 2023 and June 30, 2023, inventories amounted to $108,174 and $108,351, respectively. |
Equity Method Investments [Policy Text Block] | Equity Method Investments We apply the equity method of accounting to investments when we have significant influence, but not controlling interest in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “equity investment” in our Consolidated Statements of Operations. The carrying value of our equity method investments is reported in equity investment in the Consolidated Balance Sheets. The Company’s equity method investments are reported at cost and adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company’s share of the investee’s income or loss is recorded on a one quarter lag for all equity method investments. The Company classifies distributions received from equity method investments using the cumulative earnings approach on the Consolidated Statements of Cash Flows. The Company assesses investments for impairment whenever events or changes in circumstances indicate that the carrying value of an investment may not be recoverable. The Company recorded no other-than-temporary impairment charges related to its equity method investments during the three months ended September 30, 2023 and 2022. |
Fair Value Measurement, Policy [Policy Text Block] | Fair Value Measurements Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The Company is required to use observable market data if available without undue cost and effort. The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature. |
Earnings Per Share, Policy [Policy Text Block] | Loss per Share Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the three months ended September 30, 2023 and 2022, as there are no potential shares outstanding that would have a diluted effect. |
Income Tax, Policy [Policy Text Block] | Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company did not record a valuation allowance against its deferred tax assets as of September 30, 2023, and June 30, 2023. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update 2017-11, “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II)”, which is the replacement of the Indefinite Deferral for Mandatory Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatory Redeemable Non-controlling Interests with a Scope Exception. The amendments in Part I of this Update that relate to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include down round features affect entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in Part II of this Update do not have an accounting effect. The amendments in Part I of the update are effective for fiscal year, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is assessing the impact to its accounting practices and financial reporting procedures as a result of the issuance of this standard. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 3 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block] | The following table depicts the identity of the Company’s subsidiaries: Attributable Place of Equity Name of Subsidiary Incorporation Interest % America Great Health in California USA 100 GOF Biotechnologies in California USA 75 International Institute of Great Health in California USA 100 Nutrature Health LLC in California USA 100 Sijinsai in China CHINA 60 US-China Mega Beauty Health Industry Development Co., LTD CHINA 100 |
Schedule of Differences between Reported Amount and Reporting Currency Denominated Amount [Table Text Block] | Below is a table with foreign exchange rates used for translation: September 30, 2023 Average Quarterly (average rate) Chinese Renminbi (RMB) RMB 7.2414 United States dollar ($) $ 1.00 September 30, 2023 Quarter Ended (Closing rate) Chinese Renminbi (RMB) RMB 7.2948 United States dollar ($) $ 1.00 |
INVENTORY (Tables)
INVENTORY (Tables) | 3 Months Ended |
Sep. 30, 2023 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory, Current [Table Text Block] | As of September 30, 2023 and June 30, 2023, inventory consisted of the following: September 30, June 30, 2023 2023 Raw materials $ 65,900 $ 65,900 Finished goods 42,274 42,451 Total Inventory $ 108,174 $ 108,351 |
LONG TERM LOAN (Tables)
LONG TERM LOAN (Tables) | 3 Months Ended |
Sep. 30, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Long-Term Debt Instruments [Table Text Block] | As of September 30, 2023, long term loan consisted of the following: Principal Interest Balance Received long term loan on April 27, 2021 $ 200,000 $ 97,096 $ 297,096 Received long term loan on June 3, 2021 290,000 134,910 424,910 Received long term loan on June 4, 2021 50,000 23,260 73,260 Received long term loan on June 23, 2021 30,000 13,627 43,627 Received long term loan on July 12, 2021 10,000 4,438 14,438 Received long term loan on September 1, 2021 60,000 24,953 84,953 Received long term loan on September 22, 2021 50,000 20,219 70,219 Received long term loan on September 27, 2021 50,000 20,082 70,082 Received long term loan on September 30, 2021 10,000 4,000 14,000 Received long term loan on October 29, 2021 12,138 4,662 16,800 Received long term loan on November 9, 2021 50,000 18,904 68,904 Received long term loan on November 16, 2021 140,000 52,395 192,395 Received long term loan on November 18, 2021 50,000 18,658 68,658 Received long term loan on November 29, 2021 20,000 7,342 27,342 Received long term loan on November 30, 2021 10,000 3,666 13,666 Received long term loan on October 13, 2022 21,000 4,050 25,050 Received long term loan on March 10, 2023 10,000 1,118 11,118 Received long term loan on March 14, 2023 10,000 1,096 11,096 Received long term loan on March 16, 2023 10,000 1,085 11,085 Received long term loan on April 17, 2023 30,000 2,729 32,729 Received long term loan on May 9, 2023 10,000 789 10,789 Total $ 1,123,138 $ 459,079 $ 1,582,217 |
EQUITY INVESTMENT (Tables)
EQUITY INVESTMENT (Tables) | 3 Months Ended |
Sep. 30, 2023 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Equity Method Investments [Table Text Block] | The following table summarizes the income statement of Purecell. From 07/01/2023 to 09/30/2023 (Unaudited) Sales $ - Gross profit 22,869 Net loss (67,871 ) 51% share (36,614 ) As of September 30, 2023 (Unaudited) Total assets $ 3,223,885 Net assets 2,248,575 51% ownership 1,146,773 Beginning balance of investment 5,450 Loss on equity investment (5,450 ) Ending balance of investment - |
LEASE (Tables)
LEASE (Tables) | 3 Months Ended |
Sep. 30, 2023 | |
Disclosure Text Block [Abstract] | |
Lease, Cost [Table Text Block] | Information related to the Company’s operating ROU assets and related lease liabilities are as follows: Three months ended September 30, 2023 Cash paid for operating lease liabilities $ 18,896 Weighted-average remaining lease term 1.04 Weighted-average discount rate 5 % Minimum future lease payments $ 23,423 |
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] | The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending September 30: 2023 $ 14,603 2024 8,820 2025 - 2026 - Total minimum payments 23,423 Less: imputed interest (319 ) Total lease liability 23,104 Less: short-term lease liability (23,104 ) Long-term lease liability $ - |
NATURE OF BUSINESS (Details)
NATURE OF BUSINESS (Details) | 3 Months Ended | |||||||||||||||||
Nov. 25, 2022 | Apr. 20, 2022 shares | Mar. 31, 2022 shares | Nov. 11, 2021 $ / shares shares | Sep. 03, 2021 USD ($) | Jul. 09, 2021 USD ($) | Dec. 07, 2020 USD ($) | Jun. 30, 2020 shares | Jan. 19, 2017 USD ($) shares | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Jun. 30, 2023 USD ($) | Nov. 26, 2022 USD ($) | Jun. 30, 2022 USD ($) | Nov. 15, 2021 shares | Nov. 04, 2021 | Apr. 06, 2021 | Feb. 04, 2021 | |
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||||||||||
Stock Issued During Period, Shares, Acquisitions (in Shares) | shares | 510,000,000 | 16,155,746,000 | ||||||||||||||||
Proceeds from Sales of Business, Affiliate and Productive Assets | $ 100 | |||||||||||||||||
Payments to Acquire Investments | $ 50,000 | |||||||||||||||||
Number of Units in Real Estate Property | 53 | |||||||||||||||||
Number of Real Estate Properties | 19 | |||||||||||||||||
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross | $ 7,626,286.37 | |||||||||||||||||
Payments to Acquire Real Estate | $ 7,000,000 | |||||||||||||||||
Real Estate, Description of Terms | $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence. On September 9, 2021, the Company entered into a Supplemental Assets Acquisition Agreement with Wang’s Property Investment & Management LLC to amend and clarify that (i) it was purchasing 19 real estate properties which includes 53 units appraised at $7,626,286.37 for a purchase price of $7,000,000 and (ii) that it will waive and not conduct due diligence in order for the transaction to proceed. The acquisition has not been consummated. | |||||||||||||||||
Class of Warrant or Rights, Granted (in Shares) | shares | 500,000 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares | $ 0.01 | |||||||||||||||||
Warrants and Rights Outstanding, Term | 24 months | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in Shares) | shares | 500,000 | 1,300,000 | ||||||||||||||||
Investment Owned, Balance, Shares (in Shares) | shares | 20,000,000 | |||||||||||||||||
Agreement, Description | The Company A agrees that if the patent is sold or transferred, Men Hwei, Tsai or Men Hwei, Tsai's successor may receive a 25% gain on the transfer or sale of the interest. The Company agrees to give Men Hwei, Tsai an additional 20 million AAGH shares. The Company allows Men Hwei, Tsai to use three years (from November 26, 2022 to November 25, 2025) find investors each with more than US$10 million investment. In case that no investor is found within three years, Men Hwei, Tsai agrees to return the patent to the Company, and both parties will continue to cooperate in accordance with the original contract on May 18, 2021. If Men Hwei, Tsai finds an investor with an investment of at least US$10 million within three years, and the process for Men Hwei, Tsai and its investors to apply for a new drug may last for several years, then Men Hwei, Tsai agrees that the Company will use the patented technology to develop dietary supplement that are helpful to Alzheimer’s disease. The Company will be responsible for marketing the dietary supplement. Men Hwei, Tsai is entitled to commission equaling to 8% of sales price. | |||||||||||||||||
Other Commitment | $ 34,978.48 | |||||||||||||||||
Net Income (Loss) Attributable to Parent | $ (156,980) | $ (192,754) | ||||||||||||||||
Net Cash Provided by (Used in) Operating Activities | (120,808) | (143,244) | ||||||||||||||||
Equity, Including Portion Attributable to Noncontrolling Interest | (4,680,038) | $ (4,032,753) | $ (4,525,836) | $ (3,860,481) | ||||||||||||||
Cash | $ 54,626 | $ 54,150 | ||||||||||||||||
Gof Biotechnologies, Inc. [Member] | ||||||||||||||||||
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||||||||||
Subsidiary, Ownership Percentage, Parent | 75% | |||||||||||||||||
Investment Owned, Balance, Shares (in Shares) | shares | 60,000,000 | |||||||||||||||||
Subsidiary, Ownership Percentage, Noncontrolling Owner | 25% | |||||||||||||||||
Purecell Group [Member] | ||||||||||||||||||
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||||||||||
Equity Method Investment, Ownership Percentage | 51% | 51% | 51% | |||||||||||||||
JV Company [Member] | ||||||||||||||||||
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||||||||||
Equity Method Investment, Ownership Percentage | 60% | |||||||||||||||||
Brilliant Healthcare Limited [Member] | ||||||||||||||||||
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||||||||||
Equity Method Investment, Ownership Percentage | 40% | |||||||||||||||||
Nutrature Health LLC [Member] | ||||||||||||||||||
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||||||||||
Equity Method Investment, Ownership Percentage | 100% | 100% | 100% | |||||||||||||||
Gof Biotechnologies, Inc. [Member] | ||||||||||||||||||
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||||||||||
Equity Method Investment, Ownership Percentage | 100% | |||||||||||||||||
International Institute of Great Health, Inc. (IIGH) [Member] | ||||||||||||||||||
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||||||||||
Equity Method Investment, Ownership Percentage | 100% | |||||||||||||||||
Corporate Joint Venture [Member] | ||||||||||||||||||
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||||||||||
Payments to Acquire Interest in Joint Venture | $ 4,200,000 | |||||||||||||||||
Co-venturer [Member] | Common Stock [Member] | ||||||||||||||||||
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||||||||||
Payments to Acquire Interest in Joint Venture | 15,000,000 | |||||||||||||||||
Co-venturer [Member] | Cash Distribution [Member] | ||||||||||||||||||
NATURE OF BUSINESS (Details) [Line Items] | ||||||||||||||||||
Payments to Acquire Interest in Joint Venture | $ 3,000,000 |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) | Sep. 30, 2023 | Jun. 30, 2023 | Sep. 30, 2022 | Nov. 04, 2021 |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Cash, FDIC Insured Amount (in Dollars) | $ 3,884 | $ 4,087 | ||
Inventory, Net (in Dollars) | 108,174 | $ 108,351 | $ 108,351 | |
Maximum [Member] | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Cash, FDIC Insured Amount (in Dollars) | $ 250,000 | |||
America Great Health California [Member] | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Equity Method Investment, Ownership Percentage | 100% | 100% | ||
GOF Biotechnologies in California [Member] | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Equity Method Investment, Ownership Percentage | 75% | 75% | ||
International Institute of Great Health [Member] | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Equity Method Investment, Ownership Percentage | 100% | 100% | ||
Nutrature Health LLC [Member] | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Equity Method Investment, Ownership Percentage | 100% | 100% | 100% | |
Sijinsai [Member] | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Equity Method Investment, Ownership Percentage | 60% | 60% | ||
US-China Mega Beauty Health Industry Development Co., LTD [Member] | ||||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||
Equity Method Investment, Ownership Percentage | 100% | 100% |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Subsidiaries | 12 Months Ended | ||
Jun. 30, 2023 | Sep. 30, 2023 | Nov. 04, 2021 | |
America Great Health California [Member] | |||
Subsidiary of Limited Liability Company or Limited Partnership [Line Items] | |||
Place of Incorporation | USA | ||
Attributable Equity Interest % | 100% | 100% | |
GOF Biotechnologies in California [Member] | |||
Subsidiary of Limited Liability Company or Limited Partnership [Line Items] | |||
Place of Incorporation | USA | ||
Attributable Equity Interest % | 75% | 75% | |
International Institute of Great Health [Member] | |||
Subsidiary of Limited Liability Company or Limited Partnership [Line Items] | |||
Place of Incorporation | USA | ||
Attributable Equity Interest % | 100% | 100% | |
Nutrature Health LLC [Member] | |||
Subsidiary of Limited Liability Company or Limited Partnership [Line Items] | |||
Place of Incorporation | USA | ||
Attributable Equity Interest % | 100% | 100% | 100% |
Sijinsai [Member] | |||
Subsidiary of Limited Liability Company or Limited Partnership [Line Items] | |||
Place of Incorporation | CHINA | ||
Attributable Equity Interest % | 60% | 60% | |
US-China Mega Beauty Health Industry Development Co., LTD [Member] | |||
Subsidiary of Limited Liability Company or Limited Partnership [Line Items] | |||
Place of Incorporation | CHINA | ||
Attributable Equity Interest % | 100% | 100% |
SUMMARY OF SIGNIFICANT ACCOUN_5
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Differences between Reported Amount and Reporting Currency Denominated Amount | Sep. 30, 2023 |
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items] | |
Foreign currency exchange rate, translation | 1 |
China, Yuan Renminbi | Balance Sheet Items [Member] | |
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items] | |
Foreign currency exchange rate, translation | 7.2948 |
Income Statement Items [Member] | China, Yuan Renminbi | |
Financial Statement Line Items with Differences in Reported Amount and Reporting Currency Denominated Amounts [Line Items] | |
Foreign currency exchange rate, translation | 7.2414 |
DEPOSITS (Details)
DEPOSITS (Details) - USD ($) | Sep. 30, 2023 | Jun. 30, 2023 |
Receivables [Abstract] | ||
Other Receivables | $ 11,836 | $ 11,836 |
INVENTORY (Details) - Schedule
INVENTORY (Details) - Schedule of Inventory - USD ($) | Sep. 30, 2023 | Jun. 30, 2023 | Sep. 30, 2022 |
Schedule Of Inventory Abstract | |||
Raw materials | $ 65,900 | $ 65,900 | |
Finished goods | 42,274 | 42,451 | |
Total Inventory | $ 108,174 | $ 108,351 | $ 108,351 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details) - Majority Shareholder [Member] - USD ($) | 3 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Jun. 30, 2023 | |
RELATED PARTY TRANSACTIONS (Details) [Line Items] | |||
Proceeds from Related Party Debt | $ 77,470 | ||
Repayments of Related Party Debt | 18,364 | ||
Notes Payable | 484,248 | $ 425,142 | |
Imputed Interest | $ 0 | $ 5,206 |
SHORT TERM LOAN (Details)
SHORT TERM LOAN (Details) - USD ($) | Sep. 30, 2023 | Jun. 30, 2023 |
Debt Disclosure [Abstract] | ||
Short-Term Debt | $ 690,551 | $ 705,216 |
LONG TERM LOAN (Details)
LONG TERM LOAN (Details) | 3 Months Ended | 12 Months Ended | ||||||||||||||||||||
May 09, 2023 USD ($) shares | Apr. 18, 2023 shares | Apr. 17, 2023 USD ($) shares | Mar. 16, 2023 USD ($) shares | Mar. 14, 2023 USD ($) shares | Mar. 10, 2023 USD ($) shares | Jan. 24, 2023 USD ($) | Jan. 13, 2023 USD ($) | Oct. 13, 2022 USD ($) shares | Sep. 09, 2022 USD ($) | Feb. 02, 2022 USD ($) shares | Nov. 29, 2021 USD ($) shares | Nov. 22, 2021 USD ($) shares | Oct. 28, 2021 USD ($) shares | Jun. 23, 2021 USD ($) | Jun. 18, 2021 USD ($) shares | Jun. 03, 2021 USD ($) | May 31, 2021 USD ($) shares | May 05, 2021 USD ($) shares | Sep. 30, 2023 USD ($) shares | Sep. 30, 2022 USD ($) | Jun. 30, 2023 USD ($) | |
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Proceeds from Issuance of Debt | $ 1,123,138 | $ 1,123,138 | ||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 16% | 20% | 20% | |||||||||||||||||||
Long-Term Debt, Term | 5 years | |||||||||||||||||||||
Interest Expense, Debt | $ 459,079 | |||||||||||||||||||||
Loans Payable [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Interest Expense, Debt | $ 56,618 | $ 52,924 | ||||||||||||||||||||
Loan #1 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Long-Term Debt, Term | 5 years | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 10,000,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 200,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Loan #2 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Proceeds from Issuance of Debt | $ 30,000 | $ 20,000 | ||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Long-Term Debt, Term | 5 years | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 240,000 | 200,000 | 500,000 | |||||||||||||||||||
Debt Instrument, Face Amount | $ 50,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Stock Shares not yet Issued (in Shares) | shares | 60,000 | |||||||||||||||||||||
Loan #3 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Long-Term Debt, Term | 5 years | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 2,850,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 270,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Number of Unrelated Parties | 5 | |||||||||||||||||||||
Loan # 4 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 1,000,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 100,000 | |||||||||||||||||||||
Loan # 5 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Long-Term Debt, Term | 5 years | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 500,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 50,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Loan #6 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 80,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 5 years | |||||||||||||||||||||
Loan # 7 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 1,540,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 60,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 5 years | |||||||||||||||||||||
Loan # 8 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 500,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 50,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 5 years | |||||||||||||||||||||
Loan # 9 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 500,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 50,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 5 years | |||||||||||||||||||||
Loan #10 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 100,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 1 year | |||||||||||||||||||||
Loan #11 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 161,840 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 12,138 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 1 year | |||||||||||||||||||||
Loan #12 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 400,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 40,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 5 years | |||||||||||||||||||||
Loan # 13 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 500,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 50,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 5 years | |||||||||||||||||||||
Loan # 14 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 1,000,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 100,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 5 years | |||||||||||||||||||||
Loan #15 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 500,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 50,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 5 years | |||||||||||||||||||||
Loan #16 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 200,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 20,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 5 years | |||||||||||||||||||||
Loan #17 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Long-Term Debt, Term | 5 years | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 100,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Loan #18 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 16% | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 100,000 | |||||||||||||||||||||
Debt Instrument, Periodic Payment | 3,000 | |||||||||||||||||||||
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid | $ 12,000 | |||||||||||||||||||||
Loan Returned [Member] | Interest Expense [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Repayments of Debt | $ 4,953 | |||||||||||||||||||||
Loan # 19 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Proceeds from Issuance of Debt | $ 21,000 | |||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 2,625,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 21,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can be normally traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 5 years | |||||||||||||||||||||
Loans Payable | $ 42,000 | |||||||||||||||||||||
Debt Instrument, Collateral | If after five years, Lian Chen chooses to use stocks to offset the loan, then the Company will issue 2,625,000 shares of common stock to Mike Wang. | |||||||||||||||||||||
Loan # 20 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 150,000 | |||||||||||||||||||||
Debt Instrument, Term | 1 year | |||||||||||||||||||||
Debt Instrument, Periodic Payment | $ 30,000 | |||||||||||||||||||||
Loan # 21 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 300,000 | |||||||||||||||||||||
Debt Instrument, Term | 1 year | |||||||||||||||||||||
Debt Instrument, Periodic Payment | $ 60,000 | |||||||||||||||||||||
Loan #22 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 1,000,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can normally be traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of the loan will be forgiven. | |||||||||||||||||||||
Stock Shares not yet Issued (in Shares) | shares | 1,000,000 | |||||||||||||||||||||
Debt Instrument, Term | 3 years | |||||||||||||||||||||
Debt Instrument, Periodic Payment | $ 6,000 | |||||||||||||||||||||
Loan #23 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 1,000,000 | 1,000,000 | ||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can normally be traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of the loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 3 years | |||||||||||||||||||||
Debt Instrument, Periodic Payment | $ 6,000 | |||||||||||||||||||||
Loan #24 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 1,000,000 | 1,000,000 | ||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can normally be traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of the loan will be forgiven. | |||||||||||||||||||||
Debt Instrument, Term | 3 years | |||||||||||||||||||||
Debt Instrument, Periodic Payment | $ 6,000 | |||||||||||||||||||||
Loan # 25 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 6,000,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 30,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can normally be traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of the loan will be forgiven. | |||||||||||||||||||||
Stock Shares not yet Issued (in Shares) | shares | 6,000,000 | |||||||||||||||||||||
Debt Instrument, Term | 3 years | |||||||||||||||||||||
Debt Instrument, Periodic Payment | $ 18,000 | |||||||||||||||||||||
Loan # 26 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 20% | |||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 1,000,000 | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,000 | |||||||||||||||||||||
Long-Term Debt, Maturities, Repayment Terms | During the investment period, if the stock can normally be traded in the stock market, and the market value of this part of AAGH stock exceeds the principal and interest of loan for 30 consecutive trading days. The remaining principal and interest of the loan will be forgiven. | |||||||||||||||||||||
Stock Shares not yet Issued (in Shares) | shares | 1,000,000 | |||||||||||||||||||||
Debt Instrument, Term | 3 years | |||||||||||||||||||||
Debt Instrument, Periodic Payment | $ 6,000 | |||||||||||||||||||||
Common Stock [Member] | Loan # 4 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 100,000 | |||||||||||||||||||||
Lian Chen [Member] | Loan # 19 [Member] | ||||||||||||||||||||||
LONG TERM LOAN (Details) [Line Items] | ||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | shares | 2,625,000 |
LONG TERM LOAN (Details) - Sche
LONG TERM LOAN (Details) - Schedule of Long-term Debt Instruments - USD ($) | 3 Months Ended | 12 Months Ended |
Sep. 30, 2023 | Jun. 30, 2023 | |
Debt Instrument [Line Items] | ||
Principal | $ 1,123,138 | $ 1,123,138 |
Imputed interest | 459,079 | |
Balance | 1,582,217 | |
Loan Received on April 27, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 200,000 | |
Imputed interest | 97,096 | |
Balance | 297,096 | |
Loan Received on June 3, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 290,000 | |
Imputed interest | 134,910 | |
Balance | 424,910 | |
Loan received on June 4, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 50,000 | |
Imputed interest | 23,260 | |
Balance | 73,260 | |
Loan Received on June 23, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 30,000 | |
Imputed interest | 13,627 | |
Balance | 43,627 | |
Loan Received on July 12, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 10,000 | |
Imputed interest | 4,438 | |
Balance | 14,438 | |
Loan Received on September 1, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 60,000 | |
Imputed interest | 24,953 | |
Balance | 84,953 | |
Loan Received on September 22, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 50,000 | |
Imputed interest | 20,219 | |
Balance | 70,219 | |
Loan Received on September 27, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 50,000 | |
Imputed interest | 20,082 | |
Balance | 70,082 | |
Loan Received on September 30, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 10,000 | |
Imputed interest | 4,000 | |
Balance | 14,000 | |
Loan Received on October 29, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 12,138 | |
Imputed interest | 4,662 | |
Balance | 16,800 | |
Loan Received on November 9, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 50,000 | |
Imputed interest | 18,904 | |
Balance | 68,904 | |
Loan Received on November 16, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 140,000 | |
Imputed interest | 52,395 | |
Balance | 192,395 | |
Loan Received on November 18, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 50,000 | |
Imputed interest | 18,658 | |
Balance | 68,658 | |
Loan Received on November 29, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 20,000 | |
Imputed interest | 7,342 | |
Balance | 27,342 | |
Loan Received on November 30, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 10,000 | |
Imputed interest | 3,666 | |
Balance | 13,666 | |
Loan Received on October 13, 2022 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 21,000 | |
Imputed interest | 4,050 | |
Balance | 25,050 | |
Loan Received on March 10, 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 10,000 | |
Imputed interest | 1,118 | |
Balance | 11,118 | |
Loan Received on March 14, 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 10,000 | |
Imputed interest | 1,096 | |
Balance | 11,096 | |
Loan Received on March 16, 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 10,000 | |
Imputed interest | 1,085 | |
Balance | 11,085 | |
Loan Received on April 17, 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 30,000 | |
Imputed interest | 2,729 | |
Balance | 32,729 | |
Loan Received on May 9, 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Principal | 10,000 | |
Imputed interest | 789 | |
Balance | $ 10,789 |
LONG TERM LOAN (Details) - Sc_2
LONG TERM LOAN (Details) - Schedule of Long-term Debt Instruments (Parentheticals) | 3 Months Ended | 12 Months Ended |
Sep. 30, 2023 | Jun. 30, 2023 | |
Loan Received on April 27, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Apr. 27, 2021 | |
Loan Received on June 3, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Jun. 03, 2021 | |
Loan received on June 4, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Jun. 04, 2021 | |
Loan Received on June 23, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Jun. 23, 2021 | |
Loan Received on July 12, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Jul. 12, 2021 | |
Loan Received on September 1, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Sep. 01, 2021 | |
Loan Received on September 22, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Sep. 22, 2021 | |
Loan Received on September 27, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Sep. 27, 2021 | |
Loan Received on September 30, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Sep. 30, 2021 | |
Loan Received on October 29, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Oct. 29, 2021 | |
Loan Received on November 9, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Nov. 09, 2021 | |
Loan Received on November 16, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Nov. 16, 2021 | |
Loan Received on November 18, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Nov. 18, 2021 | |
Loan Received on November 29, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Nov. 29, 2021 | |
Loan Received on November 30, 2021 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Nov. 30, 2021 | |
Loan Received on October 13, 2022 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Oct. 13, 2022 | |
Loan Received on March 10, 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Mar. 10, 2023 | |
Loan Received on March 14, 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Mar. 14, 2023 | |
Loan Received on March 16, 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Mar. 16, 2023 | |
Loan Received on April 17, 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | Apr. 17, 2023 | |
Loan Received on May 9, 2023 [Member] | ||
Debt Instrument [Line Items] | ||
Debt Instrument, Issuance Date | May 09, 2023 |
CONVERTIBLE, REDEEMABLE PREFE_2
CONVERTIBLE, REDEEMABLE PREFERRED STOCK (Details) - Series A Preferred Stock [Member] - $ / shares | 12 Months Ended | |
Jun. 30, 2016 | Aug. 31, 2016 | |
CONVERTIBLE, REDEEMABLE PREFERRED STOCK (Details) [Line Items] | ||
Preferred Stock, Shares Authorized | 1,000,000 | 10,000,000 |
Preferred Stock, Dividend Rate, Percentage | 4% | |
Preferred Stock, Liquidation Preference Per Share | $ 1 | |
Preferred Stock, Redemption Terms | The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”). | |
Preferred Units, Description | In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days. |
SHAREHOLDERS' DEFICIT (Details)
SHAREHOLDERS' DEFICIT (Details) | Apr. 20, 2022 shares | Mar. 31, 2022 $ / shares shares | May 26, 2021 $ / shares shares | May 11, 2021 USD ($) shares | Apr. 06, 2021 $ / shares shares | Jun. 30, 2020 shares | Jan. 19, 2017 shares | Sep. 30, 2023 shares | Jun. 30, 2023 shares |
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||
Common Stock, Shares, Issued | 21,107,018,148 | 21,090,218,148 | |||||||
Common Stock, Shares, Outstanding | 21,107,018,148 | 21,090,218,148 | |||||||
Stock Issued During Period, Shares, Acquisitions | 510,000,000 | 16,155,746,000 | |||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.075 | ||||||||
Stock Issued During Period, Shares, New Issues | 500,000 | 1,300,000 | |||||||
Imediplus Inc. [Member] | |||||||||
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||
Equity Method Investment, Ownership Percentage | 5% | ||||||||
Purecell Group [Member] | |||||||||
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||
Equity Method Investment, Ownership Percentage | 51% | 51% | 51% | ||||||
Purecell Group [Member] | Aussie Produce PTY LTD [Member] | |||||||||
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||
Equity Method Investment, Ownership Percentage | 6% | ||||||||
Imediplus Inc. [Member] | |||||||||
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||
Stock Issued During Period, Shares, Acquisitions | 70,000,000 | ||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 2,500,000 | ||||||||
Purecell Group [Member] | |||||||||
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||
Stock Issued During Period, Shares, Acquisitions | 31,212,000 | 510,000,000 | |||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 510,000,000 | 510,000,000 | |||||||
Number of shareholders | 2 | ||||||||
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture | 50,000,000 | ||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | $ 0.00001 | |||||||
Sale of Stock, Number of Shares Issued in Transaction | 71,163 | ||||||||
Purecell Group [Member] | Aussie Produce PTY LTD [Member] | |||||||||
SHAREHOLDERS' DEFICIT (Details) [Line Items] | |||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | ||||||||
Proceeds from Issuance or Sale of Equity (in Dollars) | $ | $ 2,340,000 | ||||||||
Stock Issued During Period, Shares, New Issues | 35,000,000 | 35,000,000 | |||||||
Sale of Stock, Number of Shares Issued in Transaction | 68,372 |
EQUITY INVESTMENT (Details)
EQUITY INVESTMENT (Details) | Apr. 20, 2022 shares | Mar. 31, 2022 $ / shares shares | May 26, 2021 $ / shares shares | May 11, 2021 USD ($) shares | Apr. 06, 2021 $ / shares shares | Jun. 30, 2020 shares | Jan. 19, 2017 shares | Sep. 30, 2023 |
EQUITY INVESTMENT (Details) [Line Items] | ||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.075 | |||||||
Stock Issued During Period, Shares, New Issues | 500,000 | 1,300,000 | ||||||
Stock Issued During Period, Shares, Acquisitions | 510,000,000 | 16,155,746,000 | ||||||
Purecell Group [Member] | ||||||||
EQUITY INVESTMENT (Details) [Line Items] | ||||||||
Equity Method Investment, Ownership Percentage | 51% | 51% | 51% | |||||
Purecell Group [Member] | Aussie Produce PTY LTD [Member] | ||||||||
EQUITY INVESTMENT (Details) [Line Items] | ||||||||
Equity Method Investment, Ownership Percentage | 6% | |||||||
Purecell Group [Member] | ||||||||
EQUITY INVESTMENT (Details) [Line Items] | ||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 510,000,000 | 510,000,000 | ||||||
Number of shareholders | 2 | |||||||
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture | 50,000,000 | |||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | $ 0.00001 | ||||||
Sale of Stock, Number of Shares Issued in Transaction | 71,163 | |||||||
Stock Issued During Period, Shares, Acquisitions | 31,212,000 | 510,000,000 | ||||||
Purecell Group [Member] | Aussie Produce PTY LTD [Member] | ||||||||
EQUITY INVESTMENT (Details) [Line Items] | ||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ / shares | $ 0.00001 | |||||||
Proceeds from Issuance or Sale of Equity (in Dollars) | $ | $ 2,340,000 | |||||||
Stock Issued During Period, Shares, New Issues | 35,000,000 | 35,000,000 | ||||||
Sale of Stock, Number of Shares Issued in Transaction | 68,372 |
EQUITY INVESTMENT (Details) - E
EQUITY INVESTMENT (Details) - Equity Method Investments - USD ($) | 3 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Jun. 30, 2023 | |
Schedule of Equity Method Investments [Line Items] | |||
Sales | $ 13,808 | $ 51,938 | |
Gross profit | 13,631 | 24,438 | |
51% share | (603) | (10,418) | |
Net assets | 276,918 | $ 299,129 | |
Loss on equity investment | 0 | $ 0 | |
Purecell Group [Member] | |||
Schedule of Equity Method Investments [Line Items] | |||
Sales | 0 | ||
Gross profit | 22,869 | ||
Net loss | (67,871) | ||
51% share | (36,614) | ||
Total assets | 3,223,885 | ||
Net assets | 2,248,575 | ||
Purecell Group [Member] | |||
Schedule of Equity Method Investments [Line Items] | |||
51% ownership | 1,146,773 | ||
Beginning balance of investment | 5,450 | ||
Loss on equity investment | (5,450) | ||
Ending balance of investment | $ 0 |
EQUITY INVESTMENT (Details) -_2
EQUITY INVESTMENT (Details) - Equity Method Investments (Parentheticals) - Purecell Group [Member] | Sep. 30, 2023 | Apr. 06, 2021 | Jun. 30, 2020 |
Schedule of Equity Method Investments [Line Items] | |||
Share | 51% | 51% | 51% |
Ownership | 51% | 51% | 51% |
INCOME TAXES (Details)
INCOME TAXES (Details) $ in Millions | Sep. 30, 2023 USD ($) |
Foreign Tax Authority [Member] | |
INCOME TAXES (Details) [Line Items] | |
Operating Loss Carryforwards | $ 6.5 |
LEASE (Details)
LEASE (Details) | 3 Months Ended |
Sep. 30, 2023 USD ($) | |
LEASE (Details) [Line Items] | |
Operating Lease, Expense | $ 20,277 |
GKT, Alhambra, LP [Member] | Minimum [Member] | |
LEASE (Details) [Line Items] | |
Operating Lease, Expense | 4,655.64 |
SoCal Industrial LLC [Member] | Minimum [Member] | |
LEASE (Details) [Line Items] | |
Operating Lease, Expense | $ 1,764 |
LEASE (Details) - Lease, Cost
LEASE (Details) - Lease, Cost | 3 Months Ended |
Sep. 30, 2023 USD ($) | |
Lease, Cost [Abstract] | |
Cash paid for operating lease liabilities | $ 18,896 |
Weighted-average remaining lease term | 1 year 14 days |
Weighted-average discount rate | 5% |
Minimum future lease payments | $ 23,423 |
LEASE (Details) - Lessee, Opera
LEASE (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($) | Sep. 30, 2023 | Jun. 30, 2023 |
Lessee Operating Lease Liability Maturity Abstract | ||
2023 | $ 14,603 | |
2024 | 8,820 | |
2025 | 0 | |
2027 | 0 | |
Total minimum payments | 23,423 | |
Less: imputed interest | (319) | |
Total lease liability | 23,104 | |
Less: short-term lease liability | (23,104) | $ (41,918) |
Long-term lease liability | $ 0 | $ 0 |
SUBSEQUENT EVENTS (Details)
SUBSEQUENT EVENTS (Details) - CNY (¥) ¥ in Millions | Oct. 04, 2023 | Jul. 23, 2023 |
SHOWA International Pty Ltd. [Member] | ||
SUBSEQUENT EVENTS (Details) [Line Items] | ||
Sales milestones | In addition, SHOWA shall achieve the following milestones in sales during the next four-year period of time: 150,000 bottles during year one, 300,000 bottles during year two, 600,000 during year three, 1,000,000 bottles during year four. | |
Joint Venture Agreement [Member] | Subsequent Event [Member] | ||
SUBSEQUENT EVENTS (Details) [Line Items] | ||
Registered capital | ¥ 10 | |
Required capital | ¥ 200 |